Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

11.26 -0.67 (-5.62%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.